Introduction: The primary purpose of this study was to develop a simpler prognostic model to predict overall survival for patients treated for metastatic renal cell carcinoma (mRCC) by examining variables shown in the literature to be associated with survival. Methods: We conducted a retrospective analysis of patients treated for mRCC at two Canadian centres. All patients who started first-line treatment were included in the analysis. A multivariate Cox proportional hazards regression model was constructed using a stepwise procedure. Patients were assigned to risk groups depending on how many of the three risk factors from the final multivariate model they had. Results: There were three risk factors in the final multivariate model: hemoglobin, prior nephrectomy, and time from diagnosis to treatment. Patients in the high-risk group (two or three risk factors) had a median survival of 5.9 months, while those in the intermediate-risk group (one risk factor) had a median survival of 16.2 months, and those in the low-risk group (no risk factors) had a median survival of 50.6 months. Conclusions: In multivariate analysis, shorter survival times were associated with hemoglobin below the lower limit of normal, absence of prior nephrectomy, and initiation of treatment within one year of diagnosis.
Introduction
Renal cell carcinoma (RCC) is an aggressive disease, recurring in up to 40% of patients who are initially treated for a localized tumour. 1 About one-third of patients with RCC have metastatic disease at diagnosis. 2, 3 Advances in our understanding of the biology of RCC and particularly the role of angiogenesis in the progress of the clear cell subtype have led to the development of oral tyrosine kinase inhibitors with activity mostly against vascular endothelial growth factor receptor 2 (VEGF-2). These novel targeted therapies have transformed the management of metastatic RCC (mRCC). 4, 5 More than 80% of patients achieve clinical benefit in the form of objective response to treatment or disease stabilization with tyrosine kinase inhibitors. Additionally, median overall survival with the targeted therapies is now greater than two years, which is more than double the overall survival seen in the interferon-α era.
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in the literature 8, 12 to be associated with survival, including NLR. Secondary aims were to compare our model with the MSKCC and Heng models and to analyze survival in the subset of patients on first-line sunitinib therapy.
Methods

Patients
Retrospective data were obtained from the medical records of all patients diagnosed with mRCC at two Canadian centres, from July 2007 until December 2011. The inclusion criteria of Heng and colleagues were used. 9 We recorded basic demographic, survival, and clinical data, including all variables that have been shown in the literature to be important prognostic factors in mRCC. We used an NLR categorization from the literature (≤3 vs. >3). 19 We retrospectively reviewed data from 120 patients, and included the 89 patients who received at least one cycle of active treatment; 31 patients did not receive treatment and were excluded from the analysis. Approval for this study was obtained from the Horizon Health Network Research Ethics Board.
Statistical analysis
All patients who started first-line treatment, mostly with sunitinib, were included in the analysis. The main outcome, overall survival, was defined as time from treatment initiation until death, otherwise censored at last their last followup or contact. The survival distribution and median survival were assessed via Kaplan Meier estimates. Univariate associations between overall survival and baseline demographic and clinical factors were examined. Significance was taken at p<0.05. Log-rank tests were used to test the presence of a significant difference between survival among categorical variables and overall survival. For prognostic purposes, during the model-building phase all continuous variables were dichotomized at the upper or lower levels of normal except for age, which was dichotomized at >65 years and ≤65 years.
A multivariate Cox proportional hazards regression model was constructed using a stepwise procedure to identify the most significant variables affecting the disease-free survival. The stepwise algorithm used the Aikake Information Criterion (AIC), a penalized likelihood measure, to choose a final model. When comparing two models, the model with a lower AIC value more closely resembles reality. The proportional hazards assumption of the final model was examined with a global test of proportionality. The test examines correlations between model residuals and log (time).
The internal validity of the final model was examined with a two-step bootstrap procedure. In the first step, 500 samples were drawn with replacement from the observed data. The model building strategy described above was conducted on all 500 bootstrapped data sets. Finally, the frequency with which each predictor variable appeared in the final model from all 500 samples was counted. Variables appearing in >50% of the models were retained. In the next step, an additional 500 bootstrap samples were obtained. With each sample, a Cox proportional hazards model was fit using the retained variables from the first step. Using the results from the 500 estimated models, mean parameter estimates, hazard ratios, and confidence intervals (CIs) were calculated.
A risk group variable was created by summing the number of risk factors each patient had from the final model. The area under the receiver operating characteristic curve (ROC) was used to determine the predictive accuracy of the risk group variable. Additional risk group variables were calculated using prognostic models from the literature. 8, 12 The predictive accuracy of the risk group variables from different prognostic models was assessed with the area under the ROC. Kaplan Meier curves for each of the different risk group variable were calculated.
All analyses were conducted using R version 3.0.1.
Results
Patient characteristics, treatment, and survival
Baseline characteristics are provided in Table 1 . Eighty-nine patients were treated for mRCC during the study period. First-line treatments included sunitinib, being the most common (n=71, 79.8%), followed by interferon alpha (n=14, 15.7%), pazopanib (n=2, 2.2%), sorafenib (n=1, 1.1%), and temsirolimus (n=1, 1.1%). Mean patient age was 63.1 years (standard deviation [SD] 9.9 years, range 38-88). Thirtyeight out of the 89 patients (42.7%) were metastatic at diagnosis. There were 17 patients who did not undergo nephrectomy. Of these 17 patients, seven were due to comorbidities; the remaining 10 patients did not have nephrectomy for unknown reasons. At a median followup of 24.6 months (95% CI 19.2, 39.7) for the entire cohort, the median overall survival was 20.9 months (95% CI 14.2-50.6) (Fig. 1) . By the end of the study period, 44 patients (49.4%) had died. One-year survival was 63.7% (95% CI 0.54-0.76).
Univariate analysis
Factors that were significantly associated with poor overall survival were age >65 years, absence of prior nephrectomy, non-clear-cell histology, presence of two or more metastatic sites, presence of brain metastases, time interval from diagnosis to treatment of <1 year, and hemoglobin below the lower limit of normal (Table 2) .
Prognostic model for Os in mrcc
Multivariate modelling and risk stratification in a new prognostic model There were three risk factors in the final multivariate model (Table 3) : hemoglobin, prior nephrectomy, and time from diagnosis to treatment. Hemoglobin below the lower limit of normal, absence of prior nephrectomy, and having treatment begin within one year of diagnosis were all associated with worse survival. Serum lactate dehydrogenase did not improve the fit of the model in multivariate analysis and was, therefore, not included in the final model.
Patients were assigned to risk groups depending on how many of these three risk factors they had. Patients with no risk factors were assigned to the favourable-risk group. Patients with one risk factor were assigned to the intermediate-risk group, and patients with two or three risk factors were assigned to the high-risk group. A survival plot based on these risk groups is shown in Fig 2. There were 26 patients (29.2%) in the favourable-risk group, 31 patients (34.8%) in the intermediate-risk group, and 32 patients (36%) in the high-risk group.
Patients in the high-risk group had a median survival of 5.9 months (95% CI 5.9-17.3), while those in the intermediate-risk group had a median survival of 16.2 months (95% CI 11.2-NA), and those in the low-risk group had a median survival of 50.6 months (95% CI 49.3-NA) (Fig. 2) .
Comparison between our new model and the MKSCC model
The MKSCC model classifies patients into three risk categories according to their number of risk factors: favourable-risk (no risk factors), intermediate-risk (one or two risk factors), and poor (three, four, or five risk factors). Two of our patients were classified in the favourable group. Grouping these two patients with the intermediate-risk patients would result in 42 of our patients (47.2%) being classified in the intermediate group and 47 (52.8%) in the poor group. There was no difference in survival between the two groups.
Comparison between our new model and the Heng model
The Heng model stratifies patients into three risk categories according to their number of risk factors: favourable-risk (no 2 also presents a survival plot for patients in our study, using the three risk categories of the Heng model. Twenty-one of our patients (23.6%) were in the favourablerisk group according to the Heng model, 61 (68.5%) were in the intermediate-risk group, and seven patients (7.9%) were in the high-risk group. The log-rank test showed a statistically significant difference between survival curves (chi-square=9.8, degrees of freedom=2, p=0.007). Median survival was 49.3 months for the favourable-risk group, 14.2 months for the intermediate-risk group, and 7.4 months for the high-risk group.
Two of the three risk factors in our model (hemoglobin and time from diagnosis to treatment) were also in the Heng model. Both the Heng model and our model were able to distinguish survival curves between the risk groups they Prognostic model for Os in mrcc produced. Our more parsimonious model was slightly better at predicting survival, as determined by the C-index. The bootstrap corrected C-index was 0.635 for the Heng model and 0.761 for our model. All 21 patients classified in the favourable-risk category according to the Heng model were also in the favourablerisk group in our model. One of the patients in the intermediate-risk group in the Heng model were classified in the high-risk group of our model and 17 were classified in our favourable-risk group. Five of the patients classified in our high-risk group were classified in the Heng model's intermediate-risk group.
Sub-analysis of patients treated with sunitinib
Of the 89 patients in the study, 71 were treated with sunitinib (Table 1 ). Overall survival of these patients is shown in Fig.  3 . Median survival for this group was 2.29 years. One-year survival was 67.3% (95% CI 56.3-80.5), whereas two-year survival was 53.1% (95% CI 40.7-69.2). Survival up to one year was predicted by the same variables as in our univariate analysis above: NLR, hemoglobin, prior nephrectomy, and time from treatment to diagnosis. This is not surprising, given the proportional hazards assumption. Median followup for patients receiving sunitinib was 21 months (95% CI 18.1-30.4); it was 24.6 months (95% CI 19.2, 39.7) for the entire cohort.
Discussion
In our multivariate analysis, shorter survival times were associated with hemoglobin below the lower limit of normal, absence of prior nephrectomy, and initiation of treatment within one year of diagnosis.
The NLR has been shown elsewhere to be an independent predictor of survival in patients with mRCC 13, 14 and, to our assi et al.
knowledge, it
has not yet been considered in any prognostic models. In contrast to recently published articles, our univariate analysis did not demonstrate the independent prognostic value of NLR; [13] [14] [15] [16] [17] [18] perhaps this is because only 24% of our study population had an elevated NLR. This finding should be confirmed with a much larger cohort of patients.
Our model was slightly better at predicting survival (C-index 0.761) than the Heng model (0.631). Two of the three risk factors in our model (hemoglobin and time from diagnosis to treatment) were in the Heng model, 12 as well as the 2002 version of the MKSCC model. 10 Our third risk factor, prior nephrectomy, has been shown to be independently associated with overall survival in patients receiving targeted therapy. 20 As Tagawa points out, however, most patients in prospective clinical trials previously underwent nephrectomy, and thus it is difficult to draw conclusions about this factor even though retrospective studies such as ours suggest a benefit. 21 An ongoing prospective clinical trial, the CARMENA trial, is evaluating the value of upfront nephrectomy followed by sunitinib vs. sunitinib alone without nephrectomy in metastatic clear-cell RCC. 22 Based on multiple prospective phase 3 trials, first-line oral therapy with tyrosine kinase inhibitors directed against VEGF signaling has become the standard of care for most patients with mRCC with clear-cell histology. 4, 5 In a population-based study, the introduction of first-line sunitinib was associated with a doubling of overall survival compared with patients treated with interferon alone 23 and it has a manageable safety profile. 24 We were particularly interested in prognostic factors for patients receiving sunitinib. Survival up to one year was predicted by the same variables as in our univariate analysis for the entire study population: hemoglobin, prior nephrectomy, and time from treatment to diagnosis. Barnias etal produced a model for patients treated with sunitinib with three prognostic factors: time from diagnosis to initiation of treatment (as in our analysis), number of metastatic sites, and performance status. 6 There are limitations to this study, including its retrospective design and the relatively small number of patients included in the analysis. There were missing data for some of the prognostic variables in the patient charts, which may have biased our results.
Our model is simpler and could be validated in a large data bank registry, such as the International Metastatic Renal-Cell Carcinoma Database Consortium or the Canadian Kidney Cancer Information System.
Conclusion
Prognostic models using clinical and laboratory-based variables remain the primary tool for predicting outcomes in mRCC. Our study adds a new set of real-world data to the international efforts to develop better prognostic models.
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